Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


doi:10.1378/chest.06-0931
(Chest. 2007; 131:1282-1288)
© 2007 American College of Chest Physicians
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow Cited by other online articles
Google Scholar
Right arrow Articles by Khurana, V.
Right arrow Articles by Owens, M. W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khurana, V.
Right arrow Articles by Owens, M. W.
Related Content
Right arrowRelated Editorial

Statins Reduce the Risk of Lung Cancer in Humans*

A Large Case-Control Study of US Veterans

Vikas Khurana, MD; Hanmanth R. Bejjanki, MD; Gloria Caldito, PhD and Michael W. Owens, MD

* From the Department of Medicine (Drs. Khurana, Bejjanki, and Owens), Overton Brooks VA Medical Center; and Department of Biometry (Dr. Caldito), Louisiana State University Health Sciences Center, Shreveport, LA.

Correspondence to: Vikas Khurana, MD, Overton Brooks VAMC, East Stoner Ave, 151 (Research), Shreveport, LA 71101; e-mail: khuranav{at}gmail.com

Abstract

Background: Statins are commonly used cholesterol-lowering agents that are noted to suppress tumor cell growth in several in vitro and animal models.

Methods: We studied the association of lung cancer and the use of statins in patients enrolled in the Veterans Affairs (VA) Health Care System. A retrospective case-control study nested in a cohort study was conducted using prospectively collected data from the Veterans Integrated Service Networks 16 VA database from 1998 to 2004. We analyzed data on 483,733 patients from eight states located in south central United States. The primary variables of interest were lung cancer and the use of statins prior to the diagnosis of lung cancer. Multiple logistic regression analysis was done to adjust for covariates including age, sex, body mass index, smoking, diabetes, and race. Statistical software was used for statistical computing.

Results: Of the 483,733 patients in the study, 163,662 patients (33.8%) were receiving statins and 7,280 patients (1.5%) had a primary diagnosis of lung cancer. Statin use > 6 months was associated with a risk reduction of lung cancer of 55% (adjusted odds ratio, 0.45; 95% confidence interval, 0.42 to 0.48; p < 0.01). Furthermore, the protective effect of statin was seen across different age and racial groups and was irrespective of the presence of diabetes, smoking, or alcohol use.

Conclusions: Statins appear to be protective against the development of lung cancer, and further studies need to be done to define the clinical utility of statins as chemo protective agents.

Key Words: lung cancer • pharmacology • preventive medicine


Related Editorial

Statins and Lung Cancer Risk
Jhanelle Gray, W. Michael Alberts, and Gerold Bepler
Chest 2007 131: 1274-1275. [Full Text]



This article has been cited by other articles: (Search Google Scholar for Other Citing Articles)


Home page
ChestHome page
J. Gray, W. M. Alberts, and G. Bepler
Statins and Lung Cancer Risk
Chest, May 1, 2007; 131(5): 1274 - 1275.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Chest Physicians.